Cargando…

Apixaban/lopinavir/ritonavir interaction: An increase in drug level leading to high antifactory-Xa activity following drug-drug interaction: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417616/ http://dx.doi.org/10.1007/s40278-021-01591-0

Ejemplares similares

High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
por: Macías, Juan, et al.
Publicado: (2020)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
por: Agarwal, Shubham, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir/tacrolimus interaction: Increased tacrolimus level secondary to pharmacokinetic drug interaction and off label use: case report
Publicado: (2021)

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021)

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
por: Ye, Linhu, et al.
Publicado: (2021)

Chloroquine/lopinavir/ritonavir/umifenovir: QTc interval prolongation, drug interaction and off-label use: 2 case reports
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
por: Magro, Paola, et al.
Publicado: (2021)

Lopinavir/ritonavir/sirolimus interaction: Hepatitis following an off-label use: case report
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Drug ineffectiveness following off-label use in COVID-19 infection: case report
Publicado: (2022)

Immunosuppressants/Lopinavir/ritonavir: Elevated drug level, Covid 19 and reactivation of Herpes Zoster: 2 case reports
Publicado: (2020)

Drug‐Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
por: Bashir, Babar, et al.
Publicado: (2018)

Lopinavir/ritonavir/rocuronium bromide interaction: Myopathy following off-label use: case report
Publicado: (2021)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports
Publicado: (2020)

Lopinavir/ritonavir/oseltamivir/warfarin interaction: Increase in the INR and alanine aminotransferase following off label use: 10 case reports
Publicado: (2020)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
por: Svedmyr, Anders, et al.
Publicado: (2022)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Relapse or persisting shedding of COVID-2019 , increased level of tacrolimus and off-label use: case report
Publicado: (2021)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Lopinavir/ritonavir: Hyperlipidaemia following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report
Publicado: (2020)

Lopinavir/ritonavir: Diarrhoea following off label use: case report
Publicado: (2021)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes
por: Grossman, Zehava, et al.
Publicado: (2014)

Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: Sindelar, Morganne, et al.
Publicado: (2023)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Lopinavir/ritonavir: Maculopapular rash following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Acute liver failure following compassionate use: case report
Publicado: (2020)

Lopinavir/ritonavir: Cardiotoxicities following off-label use: 4 case reports
Publicado: (2021)

Lopinavir/ritonavir: Nausea and vomiting following off label use: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_frshq94hb33bm5dtpdutkorn4d